Management of STEMI in Resource-Limited Settings
A pharmaco-invasive strategy—fibrinolysis followed by planned angiography at 3-24 hours—is the most feasible and desirable pathway for STEMI management in resource-limited settings, particularly when primary PCI cannot be delivered within 120 minutes of presentation. 1
Initial Triage and Immediate Medical Therapy
At First Medical Contact (Any Level Facility)
- Administer chewable/soluble aspirin 300-350 mg stat (non-enteric coated) immediately upon suspicion of acute coronary syndrome, even before ECG confirmation 1
- Obtain 12-lead ECG within 10 minutes of arrival if equipment available 1
- If no ECG capability exists and high suspicion for MI, transfer immediately to closest facility with ECG 1
Once STEMI Confirmed
- Clopidogrel 300 mg if patient <75 years or 75 mg if ≥75 years 1
- High-dose statin: Atorvastatin 80 mg or Rosuvastatin 40 mg 1
- Beta-blockers and ACE inhibitors as appropriate 1
Reperfusion Strategy Selection
Primary Decision Algorithm
The critical time thresholds determine your approach:
- If primary PCI can be performed within 90-120 minutes of first medical contact: Transfer for primary PCI 1, 2
- If fibrinolysis can be given >60 minutes before PCI would be available: Proceed with fibrinolytic therapy 1
- If presenting within first 2 hours of symptom onset: Fibrinolysis outcomes are similar to or better than delayed primary PCI 1
The Golden Hour Principle
- Reperfusion within the first 60 minutes of symptom onset provides 50% mortality reduction 1
- Every minute of delay matters—fibrinolysis can be administered faster than arranging transfer for PCI in most resource-limited settings 1
Fibrinolytic Therapy Implementation
Agent Selection
Streptokinase is the most commonly available and cost-effective option in resource-limited settings 1, though tenecteplase and alteplase (accelerated infusion) show superior mortality outcomes when available 3
- Streptokinase plus parenteral anticoagulants has 14% higher mortality risk compared to accelerated alteplase 3
- Tenecteplase shows trend toward lower bleeding risk (RR 0.79) compared to other regimens 3
- Avoid adding glycoprotein IIb/IIIa inhibitors to fibrinolytic therapy—this increases major bleeding risk by 1.27-8.82 times without mortality benefit 3
Pre-Fibrinolysis Checklist
- Verify no absolute or relative contraindications using standardized checklist 1
- Ensure aspirin and clopidogrel already administered 1
- Initiate parenteral anticoagulation (unfractionated heparin or LMWH) 3, 4
The Pharmaco-Invasive Strategy (Preferred Approach)
This is the most practical and evidence-based pathway for resource-limited settings 1:
Step 1: Immediate Fibrinolysis
- Administer fibrinolytic at facility with thrombolytic capability 1
- Continue dual antiplatelet therapy and anticoagulation 4
Step 2: Risk Stratification Post-Fibrinolysis
For hemodynamically stable patients:
- Plan transfer for angiography at 3-24 hours after fibrinolysis 1
- Monitor for signs of failed reperfusion (persistent chest pain, <50% ST-segment resolution at 90 minutes) 1
For high-risk patients requiring immediate transfer:
- Hemodynamic or electrical instability 1
- Left ventricular dysfunction 1
- Elderly patients 1
- Failed fibrinolysis (rescue PCI needed immediately) 1
Step 3: Selective Angiography Strategy
In severely resource-constrained settings where routine post-lysis angiography is not feasible:
- Triage only high-risk patients (above criteria) to catheterization 1
- Use noninvasive risk stratification for stable low-risk patients: predischarge exercise treadmill test or stress imaging 1
- Refer for angiography only if inducible ischemia demonstrated 1
Hub-and-Spoke System of Care
Establish tiered facility levels with clear transfer protocols 1:
Level 1 (Minimal Capability)
- No ECG available
- Give aspirin, arrange immediate transfer 1
Level 2 (ECG Capability)
Level 3 (Fibrinolysis Capability)
Level 4 (PCI Capability Without 24/7 Availability)
Level 5 (Hub Center)
Late Presenters (>12 Hours)
For patients presenting >12 hours after symptom onset without ongoing symptoms or hemodynamic instability:
- Stabilize with medical therapy (aspirin, clopidogrel, beta-blockers, ACE-inhibitors, high-dose statins) 1
- Perform noninvasive evaluation for inducible ischemia 1
- Reserve invasive strategy for those with positive stress testing 1
Cost Considerations and Practical Implementation
Stent Selection
- Bare metal stents are acceptable for cost constraints, though drug-eluting stents have better long-term outcomes 1
- Consider drug-eluting stents for high-risk subsets when feasible 1
Multivessel Disease Management
- If hemodynamically stable, consider complete revascularization during index procedure to reduce need for repeat procedures 1
- This approach upgraded to Class IIa recommendation in recent guidelines 1
System-Level Requirements
- Establish contractual arrangements between hub and spoke hospitals 1
- Create cashless payment systems to eliminate upfront out-of-pocket barriers 1
- Implement performance measures for quality improvement (educational, not punitive) 1
Critical Pitfalls to Avoid
- Never delay fibrinolysis waiting for transfer if PCI cannot be achieved within 120 minutes 1
- Do not add glycoprotein IIb/IIIa inhibitors to fibrinolytic regimens—bleeding risk outweighs benefit 3
- Avoid using streptokinase when tenecteplase or accelerated alteplase available—mortality difference is significant 3
- Do not skip the pharmaco-invasive strategy in favor of fibrinolysis alone when angiography is accessible within 3-24 hours 1